Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pro Medicus Limited (AU:PME)
ASX:PME
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
0.6Last Year’s EPS
0.45Same Quarter Last Year
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: -0.77%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook, with record financial results and significant contract wins highlighting growth. However, challenges such as the radiologist workforce shortage and pricing pressure from competitors present ongoing hurdles.Company Guidance
During the recent call, Pro Medicus announced several key metrics showcasing a strong performance in the first half of FY25. The company reported a 31.1% increase in revenue, with profit after tax rising by 42.7%. EBIT margins improved from the high 60s to 71.9%. Their cash and other investments grew by 17.7% over six months, and they paid out a record half-year dividend, up 38.9%. Pro Medicus remains debt-free and has a forward revenue forecast of $894 million over five years. The company successfully implemented major projects with Baylor Scott & White and OHSU and secured significant contracts, including a $330 million deal with Trinity over 10 years and an $8 million renewal with Mercy. Additionally, the U.S. market now contributes approximately 90% of their revenue, driven by the Visage 7 product.Record Financial Performance
Pro Medicus achieved a record first half with revenue up 31.1%, profit after tax up 42.7%, and EBIT margins increasing to 71.9%. Cash and investments grew by 17.7%, and a record half-year dividend was paid out, up 38.9%.
Significant Contract Wins
Major contracts include a $330 million 10-year deal with Trinity, an $8 million renewal with Mercy over 8 years, and a $32 million 5-year renewal with a large risk client in Australia.
Strong Pipeline and New Contracts
New contract wins include U Kentucky and BayCare in Florida. The forward revenue has jumped to $894 million over 5 years, with potential upside from existing contracts.
Technological Advancements and AI Progress
Pro Medicus continues to advance in cloud technology and AI, with the first implementation of cardiology products scheduled for April. Their Visage 7 platform is well-suited for AI integration.
---
AU:PME Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AU:PME Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | AU$288.31 | AU$279.08 | -3.20% |
| Aug 13, 2024 | AU$131.40 | AU$140.80 | +7.15% |
| Feb 14, 2024 | AU$107.74 | AU$93.70 | -13.04% |
| Aug 14, 2023 | AU$69.23 | AU$72.11 | +4.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pro Medicus Limited (AU:PME) report earnings?
Pro Medicus Limited (AU:PME) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Pro Medicus Limited (AU:PME) earnings time?
Pro Medicus Limited (AU:PME) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pro Medicus Limited stock?
The P/E ratio of Pro Medicus Limited is N/A.
What is AU:PME EPS forecast?
AU:PME EPS forecast for the fiscal quarter 2025 (Q4) is 0.6.
---